Skip to main content

People

The strength of I²D³ lies in the people behind it. Our community brings together leading scientists in pharmacokinetics, peptide design, and antibody engineering, alongside collaborators in biotech, data science, and clinical practice. Together, we’re building the expertise and partnerships needed to transform drug development from the inside out.

Leadership

Gaurav Bhardwaj Headshot

Gaurav Bhardwaj

PhD – Co-Director, Peptide Design

Leader in computational peptide design andAI-enabled drug delivery.

Nina Isoherranen Headshot

Nina Isoherranen

PhD – Co-Director, PBPK Modeling

Internationally recognized expert in drug metabolism and translational PK; integrates ML into predictive PBPK modeling.

Marco Pravetoni Headshot

Marco Pravetoni

PhD – Co-Director, Antibody Engineering

Pioneer in immunotherapeutics and drug-delivery platforms.

Member Labs

  • Jay Panyam
  • Rheem Totah
  • Abhi Nath
  • David Baker

Scientific Advisors

  • Vishva Dixit — Physiological Chemistry, Genentech
  • John Karanicolas — Head of Computational Drug Discovery, AbbVie
  • Neil McDonnell — CEO, Seal Rock Therapeutics
  • Brooke Rock — ED, Pharmacokinetics and Drug Metabolism, Amgen
  • Josh Pearson — Vice President, head of PDMB, Merck Research Labs
  • Peter Senter — Retired, Pfizer / Seattle Genetics
  • Matt Thomlinson — Chief Technology Officer, Electronic Arts
AI designed protein structures from the Baker Lab

Our Team & Trainees

We train cross-disciplinary scientists at the AI–pharmaceutics interface using a co-mentorship model (two faculty + one biotech mentor), building ADME expertise for biologics and hands-on experience with predictive tools.

Collaborators & Partners

UW is uniquely positioned—leveraging decades of leadership in metabolism/PK-PD, nationally ranked programs, and deep ties with partners such as Fred Hutch and the Institute for Protein Design—to serve as a regional and national hub for AI-enabled drug disposition and delivery.